Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. New York
    4. ›
  4. 10016
    5. ›
  5. GENECENTRIX INC.

GENECENTRIX INC.

Company claim

Is this your business?

Get access!

Company Details

Name: GENECENTRIX INC.
Jurisdiction: New York
Legal type: DOMESTIC BUSINESS CORPORATION
Status: Active
Date of registration: 08 Mar 2012 (13 years ago)
Entity Number: 4213987
ZIP code: 10016
County: New York
Place of Formation: New York
Address: 139 E 30TH STREET, NEW YORK, NY, United States, 10016
Principal Address: 139 E. 30TH STREET, #2A, NEW YORK, NY, United States, 10016

Shares Details

Shares issued 200

Share Par Value 0

Type NO PAR VALUE

DOS Process Agent

Name Role Address
GENECENTRIX INC DOS Process Agent 139 E 30TH STREET, NEW YORK, NY, United States, 10016

Chief Executive Officer

Name Role Address
CHRISTIAN FULLER Chief Executive Officer 139 E 30TH ST, 6TH FLOOR, NEW YORK, NY, United States, 10014

U.S. Small Business Administration Profile

Phone Number:
734-635-3439
E-mail Address:
jennyfuller@gmail.com
Contact Person:
JENNIFER FULLER
User ID:
P1636117
Trade Name:
GENECENTRIX INC

Unique Entity ID

Unique Entity ID:
YZ3PJYMC1UV9
CAGE Code:
6PXF4
UEI Expiration Date:
2025-03-20

Business Information

Doing Business As:
GENECENTRIX INC
Activation Date:
2024-04-04
Initial Registration Date:
2012-03-19

Commercial and government entity program

CAGE number:
6PXF4
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2025-03-20
CAGE Expiration:
2029-04-04
SAM Expiration:
2025-03-20

Contact Information

POC:
JENNIFER FULLER

History

Start date End date Type Value
2024-03-01 2024-03-01 Address 175 VARICK ST., 6TH FLOOR, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)
2024-03-01 2024-03-01 Address 139 E 30TH ST, 6TH FLOOR, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)
2023-07-12 2023-07-12 Address 175 VARICK ST., 6TH FLOOR, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)
2023-07-12 2024-03-01 Address 175 VARICK ST., 6TH FLOOR, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)
2023-07-12 2024-03-01 Address 246 5th avenue, NEW YORK, NY, 10001, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
240301049782 2024-03-01 BIENNIAL STATEMENT 2024-03-01
230712004447 2023-03-10 CERTIFICATE OF CHANGE BY ENTITY 2023-03-10
220301001689 2022-03-01 BIENNIAL STATEMENT 2022-03-01
200303060613 2020-03-03 BIENNIAL STATEMENT 2020-03-01
180313006227 2018-03-13 BIENNIAL STATEMENT 2018-03-01

USAspending Awards / Financial Assistance

Date:
2022-03-07
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
LEVERAGING AI TO DISCOVER NEURON-TARGETED ANTI-ADDICTION DRUGS - PROJECT SUMMARY IN THIS PROJECT, WE WILL LEVERAGE TWO ARTIFICIAL INTELLIGENCE (AI) TOOLS AND OUR COMPANY’S UNIQUE HISTORECEPTOMICS APPROACH TO RAPIDLY DISCOVER AN IMPACTFUL NEW DRUG CANDIDATE TO TREAT OPIOID USE DISORDER (OUD) RELAPSE VIA INHIBITION OF WITHDRAWAL-ASSOCIATED NEGATIVE AFFECT (HYPERKATIFEIA). THE PREMISE IS THAT, UNLIKE TRADITIONAL DRUG DISCOVERY, WHICH IS CONCEPTUALIZED STARTING FROM DRUG TARGETS (E.G., MU OPIOID RECEPTOR) AND PROCEEDS TO PHENOTYPES (E.G., PAIN RELIEF), WE CAN SELECT SPECIFIC CELLS OR TISSUES THAT CONTROL A SPECIFIC IN VIVO PHENOTYPE, IN THIS CASE HYPERKATIFEIA, AND WORK BACKWARD TO IDENTIFY A DRUG TARGET SPECIFIC FOR THOSE CELLS, FOLLOWED BY THE DISCOVERY OF A DRUG-LIKE COMPOUND THAT MODULATES THAT DRUG TARGET. THIS WOULD BE A REVOLUTIONARY NEW PARADIGM FOR OUD DRUG DISCOVERY, TRANSLATING EXTENSIVE NEUROSCIENCE KNOWLEDGE ABOUT NEURAL CIRCUITS THAT ELICIT SPECIFIC ANALGESIC, ADDICTION OR WITHDRAWAL PHENOTYPES DIRECTLY INTO DRUGS, WHICH HAS NOT BEEN DIRECT OR EFFICIENT BEFORE. THE CRITICAL TECHNICAL ADVANCE THAT MAKES THIS PARADIGM POSSIBLE IS THE CAPABILITY TO SCREEN VIRTUALLY FOR DRUG CANDIDATES TARGETED AT ANY HUMAN GENE PRODUCT. IN OTHER WORDS, THIS DRUG DISCOVERY PROCESS CAN START AGNOSTIC TO THE EVENTUAL TARGET, WITH CONFIDENCE THAT LIGANDS FOR THAT TARGET CAN RAPIDLY BE DISCOVERED ONCE IT IS IDENTIFIED. THIS ADVANCE IS MADE POSSIBLE BY OUR HISTORECEPTOMICS TECHNOLOGIES, WHICH ALLOW US TO QUERY A SPECIFIC CELL OR TISSUE AND IDENTIFY, WITH STATISTICAL SIGNIFICANCE, GENE PRODUCTS EXCLUSIVE OR MAXIMALLY SPECIFIC TO THAT TISSUE. THE ADVANCE IS ALSO MADE TEMPORALLY FEASIBLE BY TWO HISTORIC BREAKTHROUGHS IN AI: 1) ALPHAFOLD2 FROM DEEPMIND/GOOGLE, WHICH HAS PREDICTED ACCURATE 3D STRUCTURES, SUITABLE FOR VIRTUAL CHEMICAL LIBRARY SCREENING, FOR EVERY HUMAN GENE PRODUCT FOR THE FIRST TIME IN HISTORY; AND 2) BREAKTHROUGH AI BINDING AFFINITY PREDICTION FOR DRUG CANDIDATES TO 3D STRUCTURES DEVELOPED BY OUR PARTNER MOLSOFT LLC, WHICH USES A CONVOLUTIONAL NEURAL NETWORK. WE THUS AIM TO 1) ADAPT OUR CURRENT HISTORECEPTOMICS TISSUE SEARCH SOFTWARE FEATURE TO SINGLE CELL RNA SEQ DATA PROFILING OF THE HUMAN AMYGDALA AND IDENTIFY GENE PRODUCTS EXCLUSIVE TO RSPO2+ NEURONS, WHICH CONTROL HYPERKATIFEIA. 2) PERFORM AN ULTRA-LARGE VIRTUAL LIBRARY SCREEN USING OUR AI BINDING AFFINITY PREDICTION OF THE 1.5 BILLION ENAMINE REAL DATABASE OF DRUG-LIKE CHEMICAL COMPOUNDS FOR DRUG CANDIDATES THAT BIND TO THE ALPHAFOLD2-GENERATED, MANUALLY OPTIMIZED, 3D STRUCTURE OF THE THUS-IDENTIFIED GENE PRODUCT, 3) TEST VALIDATED HIT COMPOUNDS FOR THEIR ABILITY TO REDUCE THE NEGATIVE AFFECT OF PROTRACTED OPIOID ABSTINENCE AND RELAPSE IN VIVO. A DRUG TARGETING REINSTATEMENT IN PEOPLE SUFFERING FROM OUD IS ARGUABLY MORE IMPACTFUL THAN OTHER ANTI-ADDICTION APPROACHES, BECAUSE IT COULD SYNERGIZE WITH MEDICATION-ASSISTED TREATMENT (MAT), PSYCHOSOCIAL THERAPIES AND COMMUNITY-BASED RECOVERY SUPPORTS BY NEUROCHEMICALLY REDUCING THE IMPACT OF TRIGGERS CONDITIONED BY AVOIDANCE OF WITHDRAWAL SYMPTOMS. WE WILL LEVERAGE AI TO DISCOVER SUCH A DRUG WITHIN THREE YEARS WITH MODEST INVESTMENT, WHICH WOULD BOTH ADVERTISE THE PARADIGM OF TISSUE/CELL FOCUSED DRUG DISCOVERY AND THE POWER OF AI TO ACCELERATE DRUG DISCOVERY FOR OUD/SUD.
Obligated Amount:
316719.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2019-09-18
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
BD2K PRODUCT FOR ENHANCING PHENOTYPIC SCREENS
Obligated Amount:
1472754.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2017-08-19
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
BD2K PRODUCT FOR ENHANCING PHENOTYPIC SCREENS
Obligated Amount:
150000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2015-01-09
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
NOVEL TOOL FOR LINKING DRUGS TO PHENOTYPES - I-CORPS SUPPLEMENT
Obligated Amount:
807763.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

No related officers

Related by address

No related companies by address

Date of last update: 26 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated